Medicine and Dentistry
Mortality
100%
In-Stent Restenosis
100%
Abciximab
100%
Patient
75%
Percutaneous Coronary Intervention
37%
Incidence
25%
Therapeutic Procedure
25%
Myocardial Infarction
25%
Symptom
12%
Age
12%
Follow up
12%
Diabetes Mellitus
12%
Gender
12%
Prospective Study
12%
Hypercholesterolemia
12%
Brachytherapy
12%
Patient History of Coronary Artery Bypass Graft
12%
Revascularization
12%
Heart Left Ventricle Function
12%
Directional Atherectomy
12%
Low Level Laser Therapy
12%
Low Risk Population
12%
Nursing and Health Professions
ReoPro
100%
Mortality
100%
In-Stent Restenosis
100%
Patient
75%
Percutaneous Coronary Intervention
37%
Heart Infarction
25%
Incidence
25%
Hospital
12%
Gender
12%
Follow up
12%
Symptom
12%
Patient History of Coronary Artery Bypass Graft
12%
Directional Atherectomy
12%
Low Level Laser Therapy
12%
Low Risk Population
12%
Hypercholesterolemia
12%
Revascularization
12%
Diabetes Mellitus
12%
Brachytherapy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Mortality
100%
In-Stent Restenosis
100%
Abciximab
100%
Heart Infarction
25%
Incidence
25%
Prospective Study
12%
Symptom
12%
Patient History of Coronary Artery Bypass Graft
12%
Diabetes Mellitus
12%
Hypercholesterolemia
12%
Immunology and Microbiology
Mortality
100%
Reduction (Chemistry)
100%
Abciximab
100%
Incidence
25%
Age
12%
Coronary Artery
12%
Gender
12%
Artery Bypass
12%
Heart Left Ventricle Function
12%
Low Risk Population
12%
Revascularization
12%
Neuroscience
Abciximab
100%
Myocardial Infarction
25%
Cholesterol
12%
Diabetes Mellitus
12%